Literature DB >> 11434610

Hepatopulmonary syndrome in candidates for liver transplantation.

G P Martínez1, J A Barberà, J Visa, A Rimola, J C Paré, J Roca, M Navasa, J Rodés, R Rodriguez-Roisin.   

Abstract

BACKGROUND: Hepatopulmonary syndrome (HPS) has been defined as a clinical triad, including chronic liver disease, gas exchange defects (increased alveolar-arterial PO2 difference irrespective of the presence of arterial hypoxemia), and widespread intrapulmonary vascular dilatations. We determined the incidence and the clinical and pulmonary functional characteristics of HPS in candidates for orthotopic liver transplantation (OLT) and tested their predicted accuracy.
METHODS: We studied 80 patients with cirrhosis prospectively, and carried out contrast-enhanced (CE) echocardiography and lung function tests, including ventilation-perfusion (V(A)/Q) distributions.
RESULTS: Fourteen patients had HPS (incidence, 17.5%). Patients with HPS (49 +/- 12 (+/-SD) years) had more cutaneous spiders, finger clubbing and dyspnea (P < 0.05 each) and a lower diffusing capacity (DLCO, 56 +/- 18% predicted; P < 0.001) than non-HPS patients (n = 66). Mild to moderate V(A)/Q inequalities and increased intrapulmonary shunt were predominant in HPS patients, but oxygen diffusion impairment was observed in those with hypoxemia (n = 8) only. The DLCO showed a considerable area under the receiver operating characteristic curve (0.89).
CONCLUSIONS: HPS in cirrhotic patient candidates for OLT shows a high incidence and these patients present with distinctive clinical and functional features compared with non-HPS individuals. The presence of a low DLCO may be of help for the diagnosis of HPS.

Entities:  

Mesh:

Year:  2001        PMID: 11434610     DOI: 10.1016/s0168-8278(00)00108-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

1.  Review.

Authors:  Mark Austin; Andrew J Portal; Michael Heneghan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-07

2.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 3.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

4.  Changes in arterial oxygenation after portal decompression in Budd-Chiari syndrome patients with hepatopulmonary syndrome.

Authors:  Jiaywei Tsauo; He Zhao; Xiaowu Zhang; Huaiyuan Ma; Mingshan Jiang; Ningna Weng; Xiao Li
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

5.  Pulmonary evaluation in pediatric liver transplant candidates.

Authors:  Seyed Mohsen Dehghani; Soheyla Aleyasin; Naser Honar; Ahad Eshraghian; Sara Kashef; Mahmood Haghighat; Seyed Ali Malek-Hosseini
Journal:  Indian J Pediatr       Date:  2010-10-02       Impact factor: 1.967

6.  Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation.

Authors:  Graciela Martínez-Palli; Federico P Gómez; Joan A Barberà; Miquel Navasa; Josep Roca; Robert Rodríguez-Roisin; Felip Burgos; Conchi Gistau
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

Review 7.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

8.  Liver Transplantation for Cholestatic Liver Disease.

Authors:  James Neuberger
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 9.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

10.  Hepatopulmonary syndrome: use of extracorporeal life support for life-threatening hypoxia following liver transplantation.

Authors:  Geoffrey M Fleming; Timothy T Cornell; Theodore H Welling; John C Magee; Gail M Annich
Journal:  Liver Transpl       Date:  2008-07       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.